Styrene-maleic acid-thymoquinone nanomicelles preparation, and their in vitro and in vivo application in a model of TNBC.

IF 3 Q2 PHARMACOLOGY & PHARMACY

Therapeutic delivery Pub Date : 2025-07-06 DOI:10.1080/20415990.2025.2527577

Marah Abdulhadi Alhamoud, Fatima Alhassan Hamidaddin, Mohamed Haider, Valeria Pittalà, Khaled Greish

{"title":"Styrene-maleic acid-thymoquinone nanomicelles preparation, and their in vitro and in vivo application in a model of TNBC.","authors":"Marah Abdulhadi Alhamoud, Fatima Alhassan Hamidaddin, Mohamed Haider, Valeria Pittalà, Khaled Greish","doi":"10.1080/20415990.2025.2527577","DOIUrl":null,"url":null,"abstract":"Purpose: To develop and characterize a micellar system, SMA-TQ (styrene-maleic acid-thymoquinone), for the potential management of triple-negative breast cancer (TNBC).Methods: SMA synthesis and TQ encapsulation in SMA are described. The loading of TQ in SMA-TQ was established at 20%. The size of SMA-TQ micelle as determined by DLS was in average of 155.2 nm with a polydispersity index of 0.350. In vitro testing was carried out in 4T1 TNBC cell line, and in vivo testing in mice model of TNBC.Results: In vitro experiments revealed an added effect of SMA-TQ and doxorubicin (Doxo) at doses of 1-3 mM). In vivo studies showed that the combination of SMA-TQ and Doxo had the least mean tumor growth (509.6%) compared to other treatments.Conclusion: Obtained results collectively suggest that the combination of SMA-TQ and Doxo has cumulative effects in inhibiting tumor growth, emphasizing the significance of combination therapies to enhance anticancer effectiveness. This work reveals SMA-TQ micellar system as complementary therapeutic option in TNBC.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-10"},"PeriodicalIF":3.0000,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20415990.2025.2527577","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To develop and characterize a micellar system, SMA-TQ (styrene-maleic acid-thymoquinone), for the potential management of triple-negative breast cancer (TNBC).

Methods: SMA synthesis and TQ encapsulation in SMA are described. The loading of TQ in SMA-TQ was established at 20%. The size of SMA-TQ micelle as determined by DLS was in average of 155.2 nm with a polydispersity index of 0.350. In vitro testing was carried out in 4T1 TNBC cell line, and in vivo testing in mice model of TNBC.

Results: In vitro experiments revealed an added effect of SMA-TQ and doxorubicin (Doxo) at doses of 1-3 mM). In vivo studies showed that the combination of SMA-TQ and Doxo had the least mean tumor growth (509.6%) compared to other treatments.

Conclusion: Obtained results collectively suggest that the combination of SMA-TQ and Doxo has cumulative effects in inhibiting tumor growth, emphasizing the significance of combination therapies to enhance anticancer effectiveness. This work reveals SMA-TQ micellar system as complementary therapeutic option in TNBC.

查看原文本刊更多论文

苯乙烯-马来酸-百里醌纳米微粒的制备及其在TNBC模型中的体外和体内应用。

目的：开发并表征一种胶束系统SMA-TQ（苯乙烯-马来酸-百里醌），用于三阴性乳腺癌（TNBC）的潜在治疗。方法：对SMA的合成和TQ包封进行描述。SMA-TQ中TQ的添加量为20%。DLS测定的SMA-TQ胶束尺寸平均为155.2 nm，多分散性指数为0.350。体外实验采用4T1 TNBC细胞系，体内实验采用小鼠TNBC模型。结果：体外实验显示，SMA-TQ和阿霉素（Doxo）在1 ~ 3mm剂量下有增加作用。体内研究表明，与其他治疗相比，SMA-TQ和Doxo联合治疗的平均肿瘤生长最低（509.6%）。结论：综上所述，SMA-TQ与Doxo联合用药具有抑制肿瘤生长的累积效应，强调了联合用药对提高抗癌疗效的意义。这项工作揭示了SMA-TQ胶束系统作为TNBC的补充治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic delivery PHARMACOLOGY & PHARMACY-

CiteScore

5.50

自引率

0.00%

发文量

期刊介绍： Delivering therapeutics in a way that is right for the patient - safe, painless, reliable, targeted, efficient and cost effective - is the fundamental aim of scientists working in this area. Correspondingly, this evolving field has already yielded a diversity of delivery methods, including injectors, controlled release formulations, drug eluting implants and transdermal patches. Rapid technological advances and the desire to improve the efficacy and safety profile of existing medications by specific targeting to the site of action, combined with the drive to improve patient compliance, continue to fuel rapid research progress. Furthermore, the emergence of cell-based therapeutics and biopharmaceuticals such as proteins, peptides and nucleotides presents scientists with new and exciting challenges for the application of therapeutic delivery science and technology. Successful delivery strategies increasingly rely upon collaboration across a diversity of fields, including biology, chemistry, pharmacology, nanotechnology, physiology, materials science and engineering. Therapeutic Delivery recognizes the importance of this diverse research platform and encourages the publication of articles that reflect the highly interdisciplinary nature of the field. In a highly competitive industry, Therapeutic Delivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients. The journal delivers this essential information in concise, at-a-glance article formats that are readily accessible to the full spectrum of therapeutic delivery researchers.